Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Daniella E. Portal"'
Autor:
Kristen R. Spencer, Daniella E. Portal, Joseph Aisner, Mark N. Stein, Jyoti Malhotra, Weichung Shih, Nancy Chan, Ann W. Silk, Shridar Ganesan, Susan Goodin, Murugesan Gounder, Hongxia Lin, Jiadong Li, Robert Cerchio, Christina Marinaro, Suzie Chen, Janice M. Mehnert
Publikováno v:
Oncotarget. 14:302-315
Autor:
Alexander J. Lazar, Roman Groisberg, Vivek Subbiah, Robert E. Brown, Daniella E Portal, Aung Naing, Neeta Somaiah, Maria Alejandra Zarzour, Cynthia E. Herzog, Jason Roszik, Anthony P. Conley, David S. Hong, Shreyaskumar Patel
Publikováno v:
Mol Cancer Ther
Overexpression of transcription factor 3 in alveolar soft part sarcoma(ASPS) results in upregulation of cell proliferation pathways. No standard treatment algorithm exists for ASPS; multikinase inhibitors[tyrosine kinase inhibitor (TKI)] and immune c
Autor:
Brian L. Strom, Shane S. Neibart, Jyoti Malhotra, Salma K. Jabbour, Daniella E Portal, Jason Roy
Publikováno v:
Pharmacoepidemiol Drug Saf
PURPOSE: Non-Infectious Pneumonitis (NIP) is a common complication of treatments for lung cancer. We know of no existing validated algorithm for identifying NIP in claims databases, limiting our ability to understand the morbidity and mortality of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2a3526d00ca756df132feac6a7462f1
https://europepmc.org/articles/PMC8578340/
https://europepmc.org/articles/PMC8578340/
Autor:
Jyoti Malhotra, Eileen White, Daniella E Portal, Joseph Aisner, Hongxia Lin, Mark N. Stein, Rebecca A. Moss, Susan Goodin, Kristen Spencer, Laurence A Doyle, Amanda Kaveney, Darlene Gibbon, Janice M. Mehnert, Joseph R. Bertino, Antoinette R. Tan
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:899-907
Given the evidence that coordinate inhibition of AKT induces autophagy, we studied the combination of the AKT inhibitor, MK-2206 with hydroxychloroquine (HCQ) in patients with advanced solid tumors. Patients were treated with weekly MK-2206 (135 mg o
Autor:
Tina M. Mayer, Stephen P. Peters, Joseph Aisner, Howard Streicher, Seena C. Aisner, Daniella E Portal, Claude Monken, Michael P. Kane, Amal Mansour, Edmund C. Lattime, Mark N. Stein, Isaac Yi Kim, Jennifer Nishioka, Eric A. Singer, Janice M. Mehnert, Malgorzata Wojtowicz, James L. Gulley, Robert E. Weiss, Weichung Shih
Publikováno v:
Cancer gene therapy
Intravesical BCG is a highly effective treatment for high-grade nonmuscle invasive bladder cancer and carcinoma in situ (CIS); however, for patients who are either resistant or become unresponsive to BCG therapy there is a need for alternative treatm
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e137-e138
Purpose/Objective(s) Treatment with concurrent chemoradiation and immune checkpoint inhibition (ICI) in patients (pts) with locally advanced or stage III/IV non-small lung cancer (NSCLC) is associated with improved PFS and OS. However, treatment is l
Autor:
Sarah E. Fenton, April K.S. Salama, Sunandana Chandra, Lucy Boyce Kennedy, Georgina V. Long, Akansha Chowdhary, Chanjuan Shi, Daniella E Portal, J. Randall Patrinely, Sara N. Horst, Marisa Palmeri, Janice M. Mehnert, Alexander M. Menzies, Douglas B. Johnson, Meghan J. Mooradian, Jeffrey A. Sosman, Elizabeth A. Scoville, Ryan J. Sullivan, Ben McGuigan
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
Immune checkpoint inhibitors (ICI) predispose patients to immune-related adverse events (irAEs). Although hepatitis is a potentially lethal toxicity, the timing and outcomes have not been well described. In this retrospective study, patients from six
Publikováno v:
World Journal of Clinical Oncology
Renal cell carcinomas (RCC) make up about 90% of kidney cancers, of which 80% are of the clear cell subtype. About 20% of patients are already metastatic at the time of diagnosis. Initial treatment is often cytoreductive nephrectomy, but systemic the
Autor:
Ann W. Silk, Bernard A. Fox, Jacqueline Norrell, Praveen K. Bommareddy, Jennifer L. Bryan, Daniella E Portal, Janice M. Mehnert, Seymour Fein, Joshua A. Vieth, Casey Imbergamo, Leslie Guerreiro, Cai Wu, Edwin Zambrano-Acosta, Steven J. O'Day, Andrew Zloza, Carmen Ballesteros-Merino, Marisa Palmeri, Howard L. Kaufman, Mark Grose, Daniel J. Medina, Darren R. Shafren
Publikováno v:
Cancer Research. 81:CT139-CT139
Background: Coxsackievirus A21 (V937) is an RNA oncolytic virus targeting ICAM-1 receptors. Pharmacodynamic effects of oncolytic viruses in the tumor microenvironment (TME), including increased CD8+ T cells and PD-L1 expression, support their use in
Autor:
Hongxia Lin, Rebecca A. Moss, Yujie Zhao, Susan Goodin, Daniella E Portal, Mark N. Stein, Janice M. Mehnert, Antoinette R. Tan, Diana Lindquist, Neal Ready, Joseph Aisner, Darlene Gibbon, Naoko Takebe, Murugeson Gounder
Publikováno v:
Investigational new drugs. 38(3)
Background AT-101 is a BH3 mimetic that inhibits the heterodimerization of Bcl-2, Bcl-xL, Bcl-W, and Mcl-1 with pro-apoptotic proteins, thereby lowering the threshold for apoptosis. This phase I trial investigated the MTD of AT-101 in combination wit